Supplementary Table. Demographic, pharmacokinetic and genetic characteristics of the patient cohort

Study I / Study II / Total
No of patients / 93 / 57 / 150
Women, N (%) / 36 (39) / 15 (26) / 51 (34)
Age (years) / 70 (22-84) / 72 (46-87) / 71 (22-87)
Weight (kg) / 75 (45-110) / 82 (53-104) / 77 (45-110)
Warfarin dose (mg/week) / 30.0 (6.3-70.0) / 28.8 (7.5-78.8) / 29.4 (6.3-78.8)
Clinical Indication / atrial fibrillation, valvular disease, deep venous thrombosis, or occlusive arterial disease / atrial fibrillation, deep
vein thrombosis, or prosthetic valve replacement
Targeted INR / 2.0 -3.0 / 2.0 - 3.0 / 2.0 - 3.0
INR at steady state / 2.20 (1.36-4.37) / 2.36 (1.91-3.05) / 2.28 (1.36-4.37)
S-warfarin CLtotal (mL/min) / 5.34 (0.63-15.71) / 3.97 (0.58-11.52) / 4.82 (0.58-15.71)
R-warfarin CLtotal (mL/min) / 2.63 (0.84-7.29) / 2.04 (0.91-4.81) / 2.40 (0.84-7.29)
Warfarin S/R ratio / 0.61 (0.22-2.75) / 0.60 (0.28-2.38) / 0.61 (0.22-2.75)
CYP2C9 genotype N (%) / 93 / 57 / 150
*1/*1 (wild type) / 54 (58) / 34 (60) / 88 (59)
*1/*2 / 15 (16) / 11 (19) / 26 (17)
*1/*3 / 16 (17) / 9 (16) / 25 (17)
*2/*2 / 2 (2) / 3 (5) / 5 (3)
*2/*3 / 4 (5) / 0 / 4 (3)
*3/*3 / 2 (2) / 0 / 2 (1)
CYP2C19 genotype N (%) / 93 / 57 / 150
*1/*1 (wild type) / 45 (49) / 20 (35) / 65 (43)
*1/*2 / 14 (15) / 15 (26) / 29 (19)
*1/*17 / 23 (24) / 14 (25) / 37 (25)
*2/*17 / 5 (5) / 5 (9) / 10 (7)
*2/*2 / 2 (2) / 2 (3) / 4 (3)
*17/*17 / 4 (5) / 1 (2) / 5 (3)
CYP2C8 genotype N (%) / 92 / 56 / 148
*1/*1 (wild type) / 69 (75) / 45 (80) / 114 (77)
*1/*3 / 21 (23) / 9 (16) / 30 (20)
*3/*3 / 2 (2) / 2 (4) / 4 (3)
VKORC1 genotype N (%) / 92 / 56 / 148
*1/*1 (wild type) / 34 (37) / 22 (39) / 56 (38)
*1/*2 / 38 (41) / 23 (41) / 61 (41)
*2/*2 / 20 (22) / 11 (20) / 31 (21)

INR, international nomalized ratio;

The demographicand pharmacokinetic parameters are given as mean and range if not stated otherwise